ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A CROSS SECTIONAL STUDY ON THE OCCURRENCE OF THE ANTI-HCV SEROPOSITIVITY

AUTHORS:

Dr Muhammad Sarfraz Munawar, Dr Adeel Younis, Dr Farheen Younas

ABSTRACT:

Abstract: Objective: This case work aimed to find out the recent rate of occurrence of anti-hepatitis C virus antibody in cross-section of people in Multan, and to provide its comparison with the conclusion of the past research works. Methodology: The screening of a sum of 35191 persons from both genders appearing in the laboratories in various hospitals of Multan carried out for the anti-hepatitis C virus antibody in the duration of complete two years from January 2017 to December 2018. The detection of the positive tests carried out with the utilization of EVOLIS automated fourth-generation analyzer and its confirmation carried out with the utilization of COBAS e-411 random access solid phase chemo-luminescent enzyme Immune-assay. A retroactive scrutiny of 37391 persons tested in the same laboratories of the same hospitals in the duration of 2012 to 2016 suggested 5.90% anti-hepatitis C virus positivity, and we considered that retroactive work for comparison. Results: We detected the anti-hepatitis C virus antibodies in 9.01% (n: 3170) persons. The youngest subject was a five days’ male newborn and the most aged positive subject was eighty-two years old male. Most of the carriers (48%) were available with thirty to forty-nine years of age and 53.10% of the positive subjects in Multan were from female gender. The recorded prevalence of anti-hepatitis C virus antibody in the previous retroactive work study was 5.90%. Conclusion: The frequency of anti-HCV antibody in our city of Multan have increased from 5.90% to 9.01%, there is need of investigating the reasons of the increase in reach of this virus and encouragement for awareness of the subjects. KEY WORDS: Hepatitis C Virus, Antibody, Random, Screening, Detection, Newborn, Utilization, Prevalence.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.